Premium
LongoVital® and herpes labialis: a randomised, double blind, placebo‐controlled study
Author(s) -
Pedersen A
Publication year - 2001
Publication title -
oral diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.953
H-Index - 87
eISSN - 1601-0825
pISSN - 1354-523X
DOI - 10.1034/j.1601-0825.2001.70404.x
Subject(s) - placebo , medicine , herpes labialis , placebo group , double blind , group b , clinical trial , significant difference , surgery , immunology , virus , alternative medicine , pathology , herpes simplex virus
OBJECTIVE: LongoVital (LV) (DK. Reg. No. 5178/75) is a herbal‐based tablet enriched with the recommended daily doses of vitamins. The present study was undertaken to investigate possible prevention of recurrent herpes labialis (RHL) during 4 months' daily intake of LV. DESIGN: Placebo‐controlled, double‐blind, randomised, clinical trial. SUBJECTS: Fifty‐two patients with a minimum of 4 yearly HL episodes. METHODS: The patients were given either LV or placebo for 4 months and followed‐up for another 4 months. The number, duration and maximal size of lesions were assessed. RESULTS: Twenty‐seven patients (Group A) received LV and 25 patients placebo (Group B). There were no statistically significant differences between Group A and Group B with respect to number, duration and size of lesions. Within Group A, however, there was a decrease in all three parameters after 2 months' intake of LV ( P < 0.05). The decrease in the number of HL episodes in Group A lasted during the entire follow‐up period ( P < 0.05). At the end of the medication period, significantly more patients in Group A than in Group B assessed the number and duration of recurrences to be reduced compared with before the trial ( P < 0.05). CONCLUSION: LV was not superior to placebo in the prevention of RHL although subjective assessment was in favour of LV, and the LV group had less episodes after 2 months on the tablets.